Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques

Abstract

Background and Aims The CXCR4/CXCL12 complex has already been associated with progression of atherosclerosis; however, its exact role is yet unknown. The aim of this study was to analyse the expression and cellular localization of CXCL12 and its receptor CXCR4 in human carotid atherosclerotic plaques.

Methods Carotid plaques (n = 58; 31 stable, 27 unstable, based on histological characterization of plaque morphology) were obtained during carotid endarterectomy, and 10 healthy vessels were used as a control. Expression of cxcr4, cxcr7, cxcl12, ccl2/ccr2 and csf1/csf1r was analysed at mRNA, and level expression of CXCR4, CXCR7 and CXCL12 was analysed at protein level. Cellular localization was determined using consecutive and double immunohistochemical (IHC) staining and microdissection.

Results At mRNA level, cxcr4, cxcr7 and cxcl12 were significantly higher expressed in stable carotid plaques compared with controls (p = 0.011, p < 0.001 and p < 0.001). Cxcl12 mRNA expression was successively augmented toward unstable plaques (p < 0.001). At protein level, CXCR4, CXCR7 and CXCL12 expression was significantly increased in both stable (p = 0.001, p < 0.001 and p = 0.035, respectively) and unstable (p = 0.003, p < 0.001 and p = 0.045, respectively) plaques compared with controls. Using IHC, CXCR4 was particularly localized in macrophages and small neovessels. Microdissection confirmed strongest expression of cxcr4 in macrophages within atherosclerotic plaques. Leukocytes and smooth muscle cells showed cxcr4 expression as well. For cxcl12, only microdissected areas with macrophages were positive.

Conclusion Expression of CXCR4 and CXCL12 was significantly increased in both stable and unstable carotid atherosclerotic plaques compared with healthy vessels, both at mRNA and protein level. CXCR4 and CXCL12 were localized particularly in macrophages.

Keywords

carotid atherosclerosis - stable plaques - unstable plaques - CXCR4 - CXCL12

The review process for this paper was fully handled by Gregory Y. H. Lip, Editor in Chief.

• References

• 1 Abbott AL, Paraskevas KI, Kakkos SK. , et al. Systematic review of guidelines for the management of asymptomatic and symptomatic carotid stenosis. Stroke 2015; 46 (11) 3288-3301
• 2 Eckstein HH, Kühnl A, Dörfler A, Kopp IB, Lawall H, Ringleb PA. ; Multidisciplinary German-Austrian Guideline Based on Evidence and Consensus. The diagnosis, treatment and follow-up of extracranial carotid stenosis. Dtsch Arztebl Int 2013; 110 (27-28): 468-476
• 3 Pelisek J, Eckstein HH, Zernecke A. Pathophysiological mechanisms of carotid plaque vulnerability: impact on ischemic stroke. Arch Immunol Ther Exp (Warsz) 2012; 60 (06) 431-442
• 4 Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104 (04) 503-516
• 5 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340 (02) 115-126
• 6 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105 (09) 1135-1143
• 7 Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28 (11) 1897-1908
• 8 Weber C, Döring Y, Noels H. Potential cell-specific functions of CXCR4 in atherosclerosis. Hamostaseologie 2016; 36 (02) 97-102
• 9 Döring Y, Pawig L, Weber C, Noels H. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol 2014; 5: 212
• 10 Pozzobon T, Goldoni G, Viola A, Molon B. CXCR4 signaling in health and disease. Immunol Lett 2016; 177: 6-15
• 11 Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107 (05) 1761-1767
• 12 Choi WT, Yang Y, Xu Y, An J. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem 2014; 14 (13) 1574-1589
• 13 Mirabelli-Badenier M, Braunersreuther V, Viviani GL. , et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2011; 105 (03) 409-420
• 14 Hu X, Dai S, Wu WJ. , et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007; 116 (06) 654-663
• 15 Irvine KM, Andrews MR, Fernandez-Rojo MA. , et al. Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages. J Leukoc Biol 2009; 85 (02) 278-288
• 16 Chen J, Chemaly E, Liang L. , et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol 2010; 176 (04) 1705-1715
• 17 Marsch E, Sluimer JC, Daemen MJ. Hypoxia in atherosclerosis and inflammation. Curr Opin Lipidol 2013; 24 (05) 393-400
• 18 Farouk SS, Rader DJ, Reilly MP, Mehta NN. CXCL12: a new player in coronary disease identified through human genetics. Trends Cardiovasc Med 2010; 20 (06) 204-209
• 19 Kathiresan S, Voight BF, Purcell S. , et al; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41 (03) 334-341
• 20 Hyafil F, Pelisek J, Laitinen I. , et al. Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer (68)Ga-Pentixafor for PET. J Nucl Med 2017; 58 (03) 499-506
• 21 Ma W, Liu Y, Ellison N, Shen J. Induction of C-X-C chemokine receptor type 7 (CXCR7) switches stromal cell-derived factor-1 (SDF-1) signaling and phagocytic activity in macrophages linked to atherosclerosis. J Biol Chem 2013; 288 (22) 15481-15494
• 22 Tanios F, Pelisek J, Lutz B. , et al. CXCR4: a potential marker for inflammatory activity in abdominal aortic aneurysm wall. Eur J Vasc Endovasc Surg 2015; 50 (06) 745-753
• 23 Stary HC, Chandler AB, Dinsmore RE. , et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92 (05) 1355-1374
• 24 Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000; 20 (05) 1177-1178
• 25 Redgrave JN, Gallagher P, Lovett JK, Rothwell PM. Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study. Stroke 2008; 39 (06) 1722-1729
• 26 Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86 (02) 131-138
• 27 Bot I, Daissormont IT, Zernecke A. , et al. CXCR4 blockade induces atherosclerosis by affecting neutrophil function. J Mol Cell Cardiol 2014; 74: 44-52
• 28 Wendorff C, Wendorff H, Pelisek J. , et al. Carotid plaque morphology is significantly associated with sex, age, and history of neurological symptoms. Stroke 2015; 46 (11) 3213-3219
• 29 Vrijenhoek JE, Den Ruijter HM, De Borst GJ. , et al. Sex is associated with the presence of atherosclerotic plaque hemorrhage and modifies the relation between plaque hemorrhage and cardiovascular outcome. Stroke 2013; 44 (12) 3318-3323
• 30 Zernecke A, Bidzhekov K, Noels H. , et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2 (100) ra81
• 31 Yu H, Stoneman V, Clarke M. , et al. Bone marrow-derived smooth muscle-like cells are infrequent in advanced primary atherosclerotic plaques but promote atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31 (06) 1291-1299
• 32 George J, Afek A, Abashidze A. , et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2636-2641
• 33 Kirkpatrick B, Nguyen L, Kondrikova G, Herberg S, Hill WD. Stability of human stromal-derived factor-1alpha (CXCL12alpha) after blood sampling. Ann Clin Lab Sci 2010; 40 (03) 257-260
• 34 Tanaka G, Nakase I, Fukuda Y. , et al. CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV. Chem Biol 2012; 19 (11) 1437-1446
• 35 Orsini MJ, Parent JL, Mundell SJ, Marchese A, Benovic JL. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem 1999; 274 (43) 31076-31086
• 36 Bernhagen J, Krohn R, Lue H. , et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13 (05) 587-596
• 37 Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8 (07) 533-544
• 38 Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol 2014; 6 (06) a021857
• 39 França CN, Izar MCO, Hortêncio MNS. , et al. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clin Sci (Lond) 2017; 131 (12) 1215-1224
• 40 Ara T, Tokoyoda K, Okamoto R, Koni PA, Nagasawa T. The role of CXCL12 in the organ-specific process of artery formation. Blood 2005; 105 (08) 3155-3161
• 41 Tachibana K, Hirota S, Iizasa H. , et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393 (6685): 591-594
• 42 Gupta SK, Pillarisetti K, Lysko PG. Modulation of CXCR4 expression and SDF-1alpha functional activity during differentiation of human monocytes and macrophages. J Leukoc Biol 1999; 66 (01) 135-143